KU-32, a Novel Drug for Diabetic Neuropathy, Is Safe for Human Islets and Improves In Vitro Insulin Secretion and Viability

KU-32 is a novel, novobiocin-based Hsp90 inhibitor that protects against neuronal glucotoxicity and reverses multiple clinical indices of diabetic peripheral neuropathy in a rodent model. However, any drug with potential for treating diabetic complications must also have no adverse effects on the fu...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Farmer, Kevin, Williams, S. Janette, Novikova, Lesya, Ramachandran, Karthik, Rawal, Sonia, Blagg, Brian S. J., Dobrowsky, Rick, Stehno-Bittel, Lisa
التنسيق: Artigo
اللغة:Inglês
منشور في: Hindawi Publishing Corporation 2012
الموضوعات:
Research Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3503326/
https://ncbi.nlm.nih.gov/pubmed/23197975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2012/671673
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة